Evidence map›Paper›PMID 37348477›Full record

ArticleUrologia internationalis2023

Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.

Marie Mikuteit, Stefanie Zschäbitz, Christine Stöhr, Edwin Herrmann, Iris Polifka, Abbas Agaimy, Lutz Trojan, Philipp Ströbel, Frank Becker, Christian Wülfing and 21 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologia internationalis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 13 institutions in 1 country.

Marie MikuteitDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Stefanie ZschäbitzDepartment of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Christine StöhrInstitute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), Erlangen, Germany.
Edwin HerrmannDepartment of Urology, University Hospital Muenster, Muenster, Germany.
Iris PolifkaInstitute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), Erlangen, Germany.
Abbas AgaimyInstitute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), Erlangen, Germany.
Lutz TrojanDepartment of Urology, University Hospital Göttingen, Göttingen, Germany.
Philipp StröbelDepartment of Pathology, University Hospital Göttingen, Göttingen, Germany.
Frank BeckerDepartment of Urology and Pediatric Urology, University of Saarland (UKS), Homburg, Germany.
Christian WülfingInstitute of Pathology, University Hospital Göttingen, Göttingen, Germany.
Peter BarthDepartment of Urology, University of Marburg, Marburg, Germany.
Michael StöckleDepartment of Urology and Pediatric Urology, University of Saarland (UKS), Homburg, Germany.
Michael StaehlerDepartment of Urology, University Hospital Munich, Munich, Germany.
Christian StiefDepartment of Urology, University Hospital Munich, Munich, Germany.
Axel HaferkampDepartment of Urology, University Hospital Mainz, Mainz, Germany.
Markus HohenfellnerDepartment of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Stefan DuensingDepartment of Urology, University Hospital Heidelberg, Heidelberg, Germany.
Stephan Macher-GöppingerInstitute of Pathology, University Hospital Mainz, Mainz, Germany.
Bernd WullichDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Joachim NoldusDepartment of Urology, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany.
Walburgis BrennerClinic for Obstretics and Woman's Health and Department of Urology, University Medical Center, Mainz, Germany.
Frederik RoosDepartment of Urology, University Hospital Frankfurt, Frankfurt/Main, Germany.
Bernhard WalterDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Wolfgang OttoDepartment of Urology, University of Regensburg, Regensburg, Germany.
Maximilian BurgerDepartment of Urology, University of Regensburg, Regensburg, Germany.
Maximillian ErlmeierDepartment of Urology, München Klinik Bogenhausen, Munich, Germany.
Andres Jan SchraderDepartment of Urology, University Hospital Muenster, Muenster, Germany.
Arndt HartmannInstitute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), Erlangen, Germany.
Franziska ErlmeierInstitute of Pathology, University Hospital Erlangen-Nuernberg, Friedrich Alexander University (FAU), Erlangen, Germany.
Sandra SteffensDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
German Network Of Kidney Cancer
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEHeidelberg University · DEJohannes Gutenberg University Mainz · DELMU Klinikum · DEMedizinische Hochschule Hannover · DESaarland University · DEUniversitätsmedizin Göttingen · DEUniversity Hospital Münster · DEUniversity of Regensburg · DEGoethe University Frankfurt · DEMünchen Klinik Bogenhausen · DEPhilipps University of Marburg · DEUniversitätsklinik Marien Hospital Herne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGrowth arrest-specific protein 6 (Gas 6) is a ligand that plays a role in proliferation and migration of cells. For several tumor entities, high levels of Gas 6 are associated with poorer survival. We examined the prognostic role of Gas 6 in renal cell carcinoma (RCC), especially in papillary RCC (pRCC), which is still unclear.

methodsThe patients' sample collection is a joint collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of Gas 6 was determined by immunohistochemistry.

resultsIn total, Gas 6 staining was evaluable in 180 of 240 type 1 and 110 of 128 type 2 pRCC cases. Kaplan-Meier analysis disclosed no significant difference in 5-year overall survival for all pRCC nor either subtype. Also, Gas+ and Gas- groups did not significantly differ in any tumor or patient characteristics.

conclusionGas 6 was not found to be an independent prognostic marker in pRCC. Future studies are warranted to determine if Gas 6 plays a role as prognostic marker or therapeutic target in pRCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsGrowth Arrest-Specific Protein 6HumansKaplan-Meier EstimatePrognosisGrowth Arrest-Specific Protein 6Gas 6Papillary renal cell carcinomaPrognosisSurvival

Identifiers

PMID37348477
PMCPMC10413799
OpenAlexW4381715464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.